Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the ...

肝细胞癌（HCC）约占肝癌病例的 80% 至 ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by a high rate of metastasis ...

Discover a study validating the TRIUMPH machine learning model, which improves prediction of post-transplant recurrence in ...

Researchers validated the system using tissue samples from 231 patients across five hospitals. Further validation studies are ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...

A collaborative research team has successfully developed a novel fluorescent probe, SLY (Sialyl Lewis Yellow), capable of ...

Singaporean researchers have developed an artificial intelligence-powered scoring system capable of predicting the recurrence ...

Professor Jang Soo-jin of the Department of Nuclear Medicine at Cha Medical University (Director Yoon Sang-wook) and Professor Jeon Hong-jae of Hematologic Oncology Department research team led by ...